Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y, Orikasa S, Akasaka R, Chiba T, Uesugi N, Sugai T, Matsumoto T (2016) Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol 31(3):610–614

    CAS  Article  Google Scholar 

  2. 2.

    Matsuura H, Suto K, Yasuhara H, Hata H (2018) Longitudinal sloughing mucosal casts: dabigatran-induced oesophagitis. Eur Heart J 39(36):3400

    Article  Google Scholar 

  3. 3.

    Cox R, Roche E, Fairley S (2016) Novel oral anticoagulant drugs and severe oesophagitis dissecans. Intern Med J 46(12):1456–1457

    CAS  Article  Google Scholar 

  4. 4.

    Okada M, Okada K (2012) Exfoliative esophagitis and esophageal ulcer induced by dabigatran. Endoscopy 44(Suppl 2 UCTN):E23–E24

    PubMed  Google Scholar 

  5. 5.

    Wood M, Shaw P (2015) Pradaxa-induced esophageal ulcer. BMJ Case Rep pii: bcr2015211371

  6. 6.

    Zimmer V, Casper M, Lammert F (2014) Extensive dabigatran-induced exfoliative esophagitis harboring squamous cell carcinoma. Endoscopy 46(Suppl 1 UCTN):E273–E274

    PubMed  Google Scholar 

  7. 7.

    Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, Ball R, Hornbuckle K, Walsh L, Yee C (2005) Perspectives on the use of data mining in pharmacovigilance. Drug Saf 28(11):981–1007

    CAS  Article  Google Scholar 

  8. 8.

    Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GYH (2014) Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 46(8):672–678

    CAS  Article  Google Scholar 

  9. 9.

    Staerk L, Gislason GH, Lip GY, Fosbol EL, Hansen ML, Lamberts M, Bonde AN, Torp-Pedersen C, Olesen JB (2015) Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace 17(8):1215–1222. https://doi.org/10.1093/europace/euv119

    Article  PubMed  Google Scholar 

  10. 10.

    Desai JC, Chatterjee P, Friedman K, Aisenberg J (2016) Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. Am J Gastroenterol Suppl 3:13–21

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

A.D. drafted the manuscript. D.M., C.G., D.K., L.A., B.H., and A.D. conceived and designed the study. D.M., C.G., D.K., L.A., B.H., and A.D. analysed and interpreted data. D.M., C.G., D.K., L.A., B.H., and A.D. critically revised the manuscript for important intellectual content. D.M., C.G., and A.D. performed the statistical analysis. A.D. supervised the study. A.D. is the guarantor of this work.

Corresponding author

Correspondence to Antonios Douros.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mattison, D., Gravel, C., Krewski, D. et al. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis. Eur J Clin Pharmacol 76, 1045–1047 (2020). https://doi.org/10.1007/s00228-020-02877-1

Download citation